search
Back to results

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

Primary Purpose

DLBCL, Untreated, MYC Gene Rearrangement

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Lenalidomide
Rituximab
Etoposide
Doxorubicin
Vincristine
Cyclophosphamide
Prednisone
Sponsored by
The First Affiliated Hospital with Nanjing Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for DLBCL focused on measuring DLBCL, MYC Gene rearrangement, Lenalidomide, R-DA EPOCH

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Histologically confirmed DLBCL with MYC rearrangement according to WHO 2016 criteria, excluding PMBCL, PCNSL, HIV-associated lymphoma.
  2. ECOG PS 0-2
  3. Age 18-60 years old
  4. Expected survival ≥ 12 weeks
  5. A measurable or evaluable disease at the time of enrolment (diameter ≥1.5cm)
  6. Understand and voluntarily sign an informed consent form, able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

  1. Women who are pregnant or lactating. Patients have breeding intent in 12 months or cannot take effective contraceptive measures during the trial measures
  2. Active hepatitis B or hepatitis C virus infection, as well as acquired, congenital immune deficiency diseases, including but not limited to HIV infected persons
  3. Previous exposure to any anti-tumor therapy
  4. Poor hepatic and/or renal function, defined as total bilirubin, ALT, AST, Cr more than two fold of upper normal level,Ccr# 50 mL/min unless these abnormalities were related to the lymphoma
  5. History of DVT or PE within past 12 months
  6. Poor bone-marrow reserve, defined as neutrophil count less than 1.5×109/L or platelet count less than 75×109/L, unless caused by bone marrow infiltration
  7. New York Heart Association class III or IV cardiac failure; or Ejection fraction less than 50%;or history of following disease in past 6 months: acute coronary syndrome#acute heart failure#severe ventricular arrhythmia
  8. CNS or meningeal involvement
  9. Known sensitivity or allergy to investigational product
  10. Major surgery within three weeks
  11. Patients receiving organ transplantation
  12. Patients with secondary tumour, excluding cured (5 years without relapse) in situ Non-melanoma skin cancer. superficial bladder cancer, in situ cervical cancer, Gastrointestinal intramucous carcinoma and breast cancer
  13. Presence of Grade III nervous toxicity within past two weeks
  14. Active and severe infectious diseases
  15. Any potential drug abuse, medical, psychological or social conditions whichmay disturb this investigation and assessment
  16. In any conditions which investigator considered ineligible for this study
  17. Patients with histological transformation.

Sites / Locations

  • The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)Recruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

R2-DA-EPOCH

Arm Description

Outcomes

Primary Outcome Measures

maximum tolerated dose and dose limited toxicity
Overall response rate

Secondary Outcome Measures

Progressive free survival
from date of inclusion to date of progression, relapse, or death from any cause
Overall survival
from the date of inclusion to date of death, irrespective of cause

Full Information

First Posted
June 11, 2020
Last Updated
June 13, 2020
Sponsor
The First Affiliated Hospital with Nanjing Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT04432714
Brief Title
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
Official Title
A Phase II, Prospective, Single-center Study of Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Recruiting
Study Start Date
June 9, 2020 (Anticipated)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
December 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The First Affiliated Hospital with Nanjing Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The prognosis of DLBCL with MYC rearrangement is dismal. Previous study showed that lenalidomide in combination with R-CHOP showed promising therapeutic activity and that R-DA EPOCH was superior compared to R-CHOP regimen in this cohort of patients. The investigators therefore design this phase I/II study to investigate the safety and efficacy of lenalidomide in combination with R-DA EPOCH in patients with untreated MYC-rearranged DLBCL.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
DLBCL, Untreated, MYC Gene Rearrangement
Keywords
DLBCL, MYC Gene rearrangement, Lenalidomide, R-DA EPOCH

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
81 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
R2-DA-EPOCH
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Lenalidomide
Intervention Description
Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1~d10# 21days a cycle
Intervention Type
Drug
Intervention Name(s)
Rituximab
Intervention Description
Rituximab 375 mg/m2,IV, d0
Intervention Type
Drug
Intervention Name(s)
Etoposide
Intervention Description
Etoposide 50 mg/m2/day CI24h d1-d4
Intervention Type
Drug
Intervention Name(s)
Doxorubicin
Intervention Description
Doxorubicin 10 mg/m2/day CI24h d1-d4
Intervention Type
Drug
Intervention Name(s)
Vincristine
Intervention Description
Vincristine 0.4mg/m2/day CI24h d1-d4
Intervention Type
Drug
Intervention Name(s)
Cyclophosphamide
Intervention Description
Cyclophosphamide 750 mg/m2/day IV d5
Intervention Type
Drug
Intervention Name(s)
Prednisone
Intervention Description
Prednisone 60 mg/m2/bid oral or IV d1-d5
Primary Outcome Measure Information:
Title
maximum tolerated dose and dose limited toxicity
Time Frame
21 days after first cycle of R2-DA-EPOCH regimen (each cycle is 21 days)
Title
Overall response rate
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Progressive free survival
Description
from date of inclusion to date of progression, relapse, or death from any cause
Time Frame
2 years
Title
Overall survival
Description
from the date of inclusion to date of death, irrespective of cause
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically confirmed DLBCL with MYC rearrangement according to WHO 2016 criteria, excluding PMBCL, PCNSL, HIV-associated lymphoma. ECOG PS 0-2 Age 18-60 years old Expected survival ≥ 12 weeks A measurable or evaluable disease at the time of enrolment (diameter ≥1.5cm) Understand and voluntarily sign an informed consent form, able to adhere to the study visit schedule and other protocol requirements. Exclusion Criteria: Women who are pregnant or lactating. Patients have breeding intent in 12 months or cannot take effective contraceptive measures during the trial measures Active hepatitis B or hepatitis C virus infection, as well as acquired, congenital immune deficiency diseases, including but not limited to HIV infected persons Previous exposure to any anti-tumor therapy Poor hepatic and/or renal function, defined as total bilirubin, ALT, AST, Cr more than two fold of upper normal level,Ccr# 50 mL/min unless these abnormalities were related to the lymphoma History of DVT or PE within past 12 months Poor bone-marrow reserve, defined as neutrophil count less than 1.5×109/L or platelet count less than 75×109/L, unless caused by bone marrow infiltration New York Heart Association class III or IV cardiac failure; or Ejection fraction less than 50%;or history of following disease in past 6 months: acute coronary syndrome#acute heart failure#severe ventricular arrhythmia CNS or meningeal involvement Known sensitivity or allergy to investigational product Major surgery within three weeks Patients receiving organ transplantation Patients with secondary tumour, excluding cured (5 years without relapse) in situ Non-melanoma skin cancer. superficial bladder cancer, in situ cervical cancer, Gastrointestinal intramucous carcinoma and breast cancer Presence of Grade III nervous toxicity within past two weeks Active and severe infectious diseases Any potential drug abuse, medical, psychological or social conditions whichmay disturb this investigation and assessment In any conditions which investigator considered ineligible for this study Patients with histological transformation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Li Wang, M.D., Ph.D
Phone
86 25 68306034
Email
lilyw7878@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Wei Xu, M.D., Ph.D
Phone
86 25 68306034
Email
xuwei10000@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wei Xu, M.D., Ph.D
Organizational Affiliation
The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)
Official's Role
Principal Investigator
Facility Information:
Facility Name
The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210029
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Li Wang, M.D., Ph.D
Phone
86 25 68306034
Email
lilyw7878@163.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
30707764
Citation
Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, Smith SM. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 Jun 1;125(11):1830-1836. doi: 10.1002/cncr.31877. Epub 2019 Feb 1.
Results Reference
background
PubMed Identifier
27913503
Citation
Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):366-378. doi: 10.1182/asheducation-2016.1.366.
Results Reference
background
PubMed Identifier
30501868
Citation
Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.
Results Reference
background

Learn more about this trial

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

We'll reach out to this number within 24 hrs